Table 2.
CMV-Specific T-cell Immunity Measured by QuantiFERON-CMV and the Occurrence of CMV Infection in Patients With Active SLE Receiving Intense Immunosuppressants
| Outcomes | CMV-Specific T-cell Immunity, No. (%) | |||
|---|---|---|---|---|
| QF-Positive | QF-Negative | |||
| Reactive | Nonreactive | Indeterminate | Nonreactive and Indeterminate | |
| Before receiving immunosuppressants | ||||
| All patients (n = 42) | n = 16 | n = 8 | n = 18 | n = 26 |
| CMV DNAemia | 10 (62.5) | 7 (87.5) | 8 (44.4) | 15 (57.6) |
| Ref. | P = .20 | P = .29 | P = .75 | |
| CsCMVI | 4 (25) | 4 (50) | 5 (22.2) | 8 (28.6) |
| Ref. | P = .67 | P = .55 | P = .69 | |
| 1 mo after receiving immunosuppressant | ||||
| All patients (n = 35) | n = 17 | n = 11 | n = 7 | n = 18 |
| CMV DNAemia | 10 (58.8) | 11 (100) | 5 (71.4) | 16 (88.9) |
| Ref. | P = .02a | P = .56 | P = .04 | |
| CsCMVI | 2 (11.8) | 6 (54.5) | 2 (28.6) | 8 (44.4) |
| Ref. | P = .01 | P = .72 | P = .03 |
Abbreviations: CMV, cytomegalovirus; CsCMVI, clinically significant CMV infection; QF, QuantiFERON-CMV; SLE, systemic lupus erythematosus.
aFisher exact test.